Idorsia: Simcere Set to Launch QUVIVIQ for Patients in China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2025
0mins
Should l Buy ?
Source: NASDAQ.COM
Launch of QUVIVIQ in China: Simcere Pharmaceuticals has launched QUVIVIQ (daridorexant) in China, a medication developed by Idorsia for treating insomnia in adults.
Licensing Agreement Details: Idorsia and Simcere entered an exclusive licensing agreement for QUVIVIQ in Greater China, with Idorsia receiving $80 million in milestone payments and potential for further royalties.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
